drugset / Press release
Acquisition of exclusive development and commercial rights to IPH2101 in the context of a swap of products
2008-10-06 · Innate Pharma · original innate-pharma.com ↗
Innate Pharma SA announces that it has acquired the worldwide exclusive development and commercial rights to IPH2101 from Novo Nordisk A/S in the context of a swap of products. Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30
The release as fetched from its publisher. innate-pharma.com ↗